MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
The specific companies identified above may not be representative of all of Ignite500's investments and no assumption should be made that the investments identified were or will be profitable. This website uses cookies and other tracking technologies for functional and analytical purposes. Navigation beyond the homepage implies acceptance of the Terms of Use and our Privacy Policy.